echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Changes in executives of well-known multinational arms companies

    Changes in executives of well-known multinational arms companies

    • Last Update: 2020-11-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On September 15th, According to Wallian Medical, Valian's new position as global president and chief operating officer will be filled by Chris Toth, the current president of Wallian Oncology Systems.
    O'Reilly, senior vice president of global operations at the Company, will replace Taukry as president of Wallian Oncology Systems.
    , Vice President of Revenue Operations, will be appointed Senior Vice President for Global Supply Chain Operations.
    management appointments will take effect on 5 October 2020.
    Tocquery is president and chief operating officer of Wally's Security Balls Photo Source: Valian's chief medical officer, Microwarian Micro, who has nearly 20 years of industry experience and has held a number of management positions since joining Valian in 2001.
    currently president of Valian Oncology Systems, managing more than $3 billion in business and more than 7,000 employees worldwide.
    in this position, Taukry helped Wallian recover from double-digit growth.
    this position, he was President of Wally's Safety Ball Business and Field Operations, responsible for global sales strategy and execution for Valian's oncology and proton therapy business.
    Kevin O'Reilly Picture Source: Kevin O'Reilly, Wallian Officer, has over 30 years of cross-industry, cross-regional management experience.
    currently serves as Senior Vice President of Wally's Safety Ball Operations, responsible for Wally's Global Supply Chain, Revenue and Customer Support, managing $3 billion in revenue and more than 2,000 employees worldwide.
    , he served as President of Wallian Asia Pacific before joining Valian in 2009, where he held management positions at RPO, Inc. and Photoon Dynamics.
    Stephanie Foster Picture Source: Valiant Stephanie Foster currently serves as Vice President of Revenue Operations, managing contracts, sales and operations planning, logistics, installation services, and environmental health and safety.
    she joined Valian in 2019, she was Vice President of Honeywell Supply Chain, managing approximately $4 billion in revenue from the business unit that manufactures products for the defense, aerospace and aerospace industries.
    before joining Honeywell, she held management positions at OrbitalATK and Raytheon.
    2020: Siemens' acquisition of Valian is notable for the fact that, 45 days before this major personnel change, on August 2, Siemens Medical and Valian Medical Systems announced that they had signed an agreement to acquire all shares of Valian Medical Systems for $177.50 per share in cash, for a total price of approximately $16.4 billion, equivalent to approximately RMB114.38 billion.
    Siemens Medical's acquisition of Valian is expected to be completed in the first half of 2021, subject to approval by Valian shareholders and regulators, and to meet other agreed terms of acquisition.
    said it expects to continue operating as an independent company within Siemens Medical under the Valian brand after the deal is completed.
    combined company will provide a fully integrated platform covering end-to-end oncology solutions to ensure the full continuity of cancer care: from screening and diagnosis, treatment care, to post-treatment survival.
    understood that Wallian, medical science, Ancory is known in the industry as the radiotherapy industry's three giants.
    Valian's market share may have been the top three - in 2018, according to Valian's financial results, it has a global market share of more than 50 per cent and a Chinese market share of 40 per cent, while Medical Anda and Siemens are in second and third place with 32.8 per cent and 14.3 per cent respectively.
    Valian's current main business is divided into imaging originals and oncology systems (radiation therapy), according to Siyu Medical Watch combing, Valian imaging business sales in the world ranked 10th, which accounts for only 20% of all its business share.
    accounts for about 75% of its cancer radiotherapy market and 70% of the global radiotherapy market, with cancer system products accounting for about 45% and cancer system services accounting for about 30%.
    Valian's revenue for the six months to April 3 was $828 million, essentially the same as in the same period in 2019, according to the latest financial results.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.